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Complete annotation of the human genome is indispensable for medical research. The
GENCODE consortium strives to provide this, augmenting computational and experimental
evidence with manual annotation. The rapidly developing field of proteogenomics provides
evidence for the translation of genes into proteins and can be used to discover and refine
gene models. However, for both the proteomics and annotation groups, there is a lack of
guidelines for integrating this data. Here we report a stringent workflow for the interpretation
of proteogenomic data that could be used by the annotation community to interpret novel
proteogenomic evidence. Based on reprocessing of three large-scale publicly available human
data sets, we show that a conservative approach, using stringent filtering is required to
generate valid identifications. Evidence has been found supporting 16 novel protein-coding
genes being added to GENCODE. Despite this many peptide identifications in pseudogenes
cannot be annotated due to the absence of orthogonal supporting evidence.
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B
iological and biomedical research relies on complete
accurate and consistent annotation of genes and their
products. However, identifying and annotating functional
elements in the human genome is a persistent challenge.
Despite intensive study, especially in identifying protein-coding
genes, our understanding of the genome is far from complete,
particularly with regard to non-coding RNAs, alternatively
spliced transcripts and regulatory sequences. The GENCODE
consortium is carrying out the annotation of all gene features in
the reference human genome1. The annotation combines
computational analysis, targeted experimental evidence and
manual curation approaches to produce high-accuracy genome
annotations for protein-coding genes, long non-coding RNAs
(lncRNA) and pseudogenes. The reference gene set produced by
GENCODE is the default gene set available in Ensembl.
A key goal of genome annotation is to describe a complete list
of protein-coding genes. For many genes, confirmation of coding
potential and the definition of the exact gene structure are not
trivial2. Automated algorithms utilize comparative genomics
methods such as phyloCSF3 to score transcript-coding potential
while annotation groups incorporate antibody tagging4 and mass
spectrometry5–7 proteogenomic experiments. GENCODE release
(V22) contains only 19,814 protein-coding genes, decreasing
from over 20,600 protein-coding loci in release V7. This
fundamental refinement can mainly be attributed to improved
comparative and proteomics analysis methods that have indicated
transcripts with poor coding potential for removal from the
reference gene set.8
High-quality peptides from large-scale proteomics experiments
confirm coding potential, especially for genes and transcripts
where there is little other supporting evidence9,10. Proteomics
experiments only identify a fraction of detectable peptides.
A peptide may not be detected if it is not amenable to the
methods used or if the corresponding protein is not expressed in
detectable quantities in the tissue type analysed. This means that
while reliably identified peptides verify protein-coding potential,
the lack of corresponding peptides does not prove a transcript is
not translated. Despite this, the majority of protein-coding genes
in the GENCODE annotation of the human genome are routinely
identified with confident peptides in large-scale proteomics
experiments11–15.
The increased scale of proteogenomics endeavours means that
a higher false positive rate is inevitable. Recent reviews of the
proteogenomics field have highlighted the challenge posed by
false positives16,17. Target-decoy database searching is the most
common approach for determining false positive identification
rates, however, recent publications have pointed out some of the
limitations of this method18–21. To minimize erroneous
identifications, accurate estimation of error and conservative
significance filtering criteria must be applied. While initial
filtering by a false discovery rate (FDR), calculated based on
decoy identifications, is a good starting point, novel
identifications should be examined independently and assessed
by posterior error probability (PEP) and P value. The use of tools
such as Percolator can also correct for inaccuracies in FDR
estimation22. Moreover, since many peptides are only detected
occasionally, combining results from many experiments can
improve proteome coverage and confidence of novel assignments.
In addition, even with high confidence in peptide identifications
alternative explanations such as sequence variants and
contaminates must be considered. Proteogenomics experiments
have been particularly useful for poorly annotated genomes,
providing a powerful tool to validate new gene models23–25.
Proteogenomics analysis can generate large numbers of
putative novel protein-coding gene identifications. However,
there are no suitable guidelines for how this data should be
treated so that it can be successfully incorporated into genome
annotation. We present here criteria for the generation and
interpretation of proteomics evidence for novel annotations.
We describe a proteogenomic workflow encompassing a search
database, and stringent filtering criteria to refine peptide
assignments (Fig. 1). To assist annotators, we propose a priority
annotation score to rank identifications. From the annotator’s
perspective, we discuss how proteogenomics evidence can be
interpreted and what additional information substantiates
protein-coding potential for annotation. In the presented work,
we concentrate on the human genome by reanalysing human
tissue data from the draft human proteome experiments, but
these methodologies are applicable to any sequenced genome.
Results
Reanalysis of the human proteome. We have implemented the
workflow shown in Fig. 1, and used it to reprocess over 52 million
spectra from the human proteome experiments. This resulted
in 17,777,190 significant peptide spectrum matches (PSMs) cor-
responding to 342,015 distinct peptide sequences longer than
7 amino acids (aa), representing 34% of the query spectra. PSMs
were determined as significant using a 1% FDR and a 0.05 PEP
cut-off. Significant PSMs were required to identify the same
peptide with these criteria via multiple search algorithms. This
equated to a final estimated PSM q-value of 0.0007 (0.07% FDR).
The distribution of identified peptides in the search space is
shown in Fig. 2, with 99.5% matching known protein-coding
sequences (CDS). About 0.6% of these were unique to either
GENCODE or UniProt, highlighting the importance of consider-
ing multiple sequence annotation sources. These differences are
due to independent database curation and annotation efforts.
Figure 3 further breaks down the identified peptides by tissue,
showing testis and ovary tissues to have the highest total number
of peptide identifications. Testis also contained the most
tissue-specific peptides, followed by liver, spleen, brain and foetal
tissues. This observation suggests that these tissues have a
significant number of uniquely expressed genes or alternative
transcripts not found in other tissues. Other recent publications
focusing on the analysis of Testis tissue have also found this
to be true26.
Conducting protein inference and clustering to produce the
shortest list of proteins that explain all significant peptides, we
found evidence for 19,262 human proteins. For known proteins,
we mapped these proteins to their Ensembl gene identifiers,
finding evidence for 16,271 genes or clusters of genes with distinct
peptides. A cluster of genes is defined as a set of genes, usually
from the same family, which match one or more unique peptides
specific to this set. Genes that only matched a subset of peptides
from another gene were not counted in this number. About
13,852 genes were unambiguous identifications evidenced by
multiple peptides and at least 1 uniquely identifying peptide.
This is in reasonable agreement with the numbers of genes
reported in previous studies using similar levels of stringency13.
Further filtering by number of uniquely identifying peptides
produces 11,606 and 10,740 genes with 2 and 3 unique peptides,
respectively.
Among these genes, 7,716 transcripts were identified with
unique peptides revealing 1,169 genes with evidence of alternative
splicing. Further strict filtering increased the PEP threshold to
0.01, removed modified peptides, removed peptides with430 aa
and peptides with 42 missed cleavages. This additional filtering
returned 32,497 gene-specific peptides and reduced the resulting
genes with multiple different transcripts to 867. About 8,425 of
the identified peptides crossed exon boundaries in these genes.
About 1,869 transcripts mapped to these genes with 9,114 unique
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peptide mappings, and 2,956 of these peptides crossed exon
boundaries. Testis again showed the highest amount of alternative
transcription.
Identifying novelty in the proteome. About 1,406 of the
identified peptides did not match previously annotated coding
regions within known protein-coding genes in GENCODE or
UniProt. While these peptides could represent genuine novel CDS
annotations, they could also be due to false positive assignments,
or explicable as single nucleotide polymorphisms (SNPs) that lead
to single amino-acid variants (SAVs). Genuine novel CDS
annotations can take three forms: the addition of completely
novel protein-coding genes where no previous annotation existed;
the annotation of a CDS within a locus that was previously
classified as an lncRNA or pseudogene; or the addition of novel
CDS within pre-existing protein-coding genes (for example, the
identification of additional coding exons). While the novel data is
the most interesting in terms of GENCODE annotation, it is at
the highest risk of false positive identifications. We examined
these identifications and devised suitable filtering criteria and
quality measures to produce a refined set of novel peptides for
genome annotation (Fig. 4).
To generate higher confidence peptide identification, we
increased our acceptance threshold to a minimum PEP of 0.01.
Examination of the remaining spectra revealed that certain types
of peptide commonly showed poor ion series coverage casting
reasonable doubt on their assignments. As a consequence,
long peptides 429 aa, peptides with 42 missed cleavages and
semi-tryptic peptides were eliminated. In addition, we examined
the incidence of post-translationally modified PSMs by compar-
ing the enrichment of modification type in the novel data and the
CDS data. These analyses found that deamidation and N-terminal
carbamidomethylation were overrepresented among novel
identifications (Supplementary Fig. 1). We have therefore
disregarded all novel PSMs with these modifications. However,
other modifications such as oxidation and acetylation showed
similar proportions in both CDS and novel PSMs and have
been retained, they only contribute a small portion (6%) of the
novel PSMs.
The human genome has been the subject of intensive study and
annotation for many years. Hence, the chances of a peptide being
completely novel are small and an alternative explanation should
be considered. There are several repositories of human genome
annotation and these are being constantly updated with new
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Figure 1 | Proteogenomic analysis pipeline. (a) 4,917 raw files from the draft human proteome data sets14,15; containing 52,236,496 spectra comprising
61 different healthy human tissues were reprocessed. Non-normal tissue and cell lines may have compromised genomes, affecting expression of genes and
displaying genome rearrangements and were not used here. (b) A bespoke protein sequence database was created containing 4,200,154 protein
sequences. 270,908 of these redundantly mapped to known protein-coding genes and transcripts. This database comprised known protein sequences
combined with translated RNAseq data and novel gene sequences (lncRNA, pseudogenes, 50 UTR and novel gene predictions made using AUGUSTUS39).
All isoleucine residues were replaced with leucine throughout the database to avoid complications caused by isobaric peptides. These sequences were
concatenated with contaminants and decoy sequences to allow false discovery estimation. (c) Raw data was converted to mzML and searched in a
proteogenomics workflow combining multiple mass spectrometry search engines and post-search evaluation tools. Results were filtered by peptide length,
FDR, PEP and agreement between the multiple search algorithms. (d) About 34% of the spectra searched were significantly identified at a high-confidence
level, collapsing to a smaller set of unique peptide sequences. Peptides were inferred into a redundant list of proteins, and mapped to a non-redundant set
of known coding Ensembl (CDS) genes. Putative novel peptides were further filtered at an increased stringency. (e) A set of peptide features were
combined in a score and used to rank novel identifications prior to manual annotation in GENCODE.
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annotations. Each novel peptide was blasted against the latest
available GENCODE, RefSeq, NextProt and UniProt sequence
database releases to identify peptides found in updated protein-
coding annotations; 231 (7%) of the novel peptides were
eliminated in this way. Also peptides containing SAVs will not
match their corresponding protein sequence and can be
misinterpreted as novel. To account for this, all novel peptides
were required to be at least two amino acids different to any
peptide from a known protein-coding gene.
The implemented peptide filtering regime should eliminate the
majority of false positives. However, manual inspection of spectra
is recommended for key peptides, especially those determined to
provide evidence for new protein-coding regions. The final set of
650 highly confident novel PSMs mapped to 204 unique peptides
and inferred 168 possible novel protein-coding annotations,
17 with multiple peptide evidence (Supplementary Dataset 1).
In addition, any new gene annotations obtained were further
validated by mapping tissue-specific RNAseq transcript data
from the Uhle´n study27 to the corresponding gene regions
(Supplementary Fig. 4).
As part of this analysis, we proposed a priority annotation
score for each novel peptide and protein. This score used peptide
features suggested by expert annotators based on prior experi-
ence, targeting criteria that appeared to distinguish peptides that
led to annotation from those that did not. The aim of this score
was to rank novel peptides identifications, highlighting the
protein and peptide mappings most likely to lead to new
annotation. The peptide priority annotation score is based on
various peptide features that are not normally considered in PSM
scoring including the PEP, the number of PSMs observed, the
number of replicate identifications, the delta scores between top
and second rank assignments, peptide length and the amino-acid
sequence complexity. The full formula used can be found in the
online methods. The summed score of all unique peptides
identifying a novel protein was then used to rank the putative
novel protein identifications. In the context of our human
proteogenomic analysis, this score was difficult to further
optimize since, in spite of the speculative search space used,
only a few novel genes were identified. This likely reflects the
high quality of existing annotation for this reference genome.
However, all filtered novel identifications were manually
examined regardless of ranking, and we were thus able to
demonstrate a good correlation between peptide score and the
likelihood of annotation taking place (Supplementary Fig. 5). This
priority annotation score is potentially more useful for annotators
targeting non-model organism genomes, based on the presump-
tion that such gene sets are less complete in terms of protein-
coding content. However, we emphasize that the scoring system
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Figure 2 | Identified peptide types. (a) Overlap of significant peptides between known coding sequences (GENCODE CDS and UniProt), RNAseq
translations and novel proteins (50 UTR, lncRNA, pseudogenes and AUGUSTUS predictions). (b) The overlap in known CDS peptides between GENCODE
and UniProt. (c) Overlap in significant peptides between the three different RNAseq data sources. (d) Significant peptides matching non-CDS translated
sequences. (e) Overlap between the annotated novel proteins and RNAseq data. All peptides have a minimum of seven amino acids and were identified by
PSMs having an FDR o1% and posterior error probability (PEP) r0.05 based on two different search algorithms. Non-CDS peptides were reduced to a
minimum PEP of 0.01 additionally passing a strict set of filtering criteria.
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does not provide actual probability estimations; it should instead
be used to rank potential proteins. Furthermore, while a score of
B100 marks the point at which the annotation of a peptide
became probable in this study, this is unlikely to be the same for
studies on other genomes given the number of variables involved
(such as the quality of genome sequence, and the size and nature
of the proteomics data).
Discussion
Manual annotation of the multi-peptide list, containing 17
prospective protein-coding regions, led to the addition of 7
protein-coding genes to GENCODE. In addition an eighth novel
protein-coding region was created within the INPP5F protein-
coding gene as part of an alternatively spliced transcript.
Subsequently, 9 novel protein-coding genes were annotated in
the list of 151 single-peptide identifications (Table 1). In total, our
survey has led to the addition of 16 protein-coding genes to
GENCODE: 8 based on lncRNA or RNAseq models, and 8 on
pre-existing pseudogenes. The coding status of four of the
pseudogenes—MAGEB6P1, MYO15B and two CENPV-related
loci—were highlighted by Pandey et al.16, although MYO15B was
previously regarded as a coding locus by UniProt. However,
our MYO15B peptide is novel to this study and has supported the
annotation of a CDS that is 1,534 aa longer than the UniProt
entry. Two of the remaining 11 cases (HUMG00000150367
and HUMG00000158324) correspond to unreviewed entries in
UniProt; the coding potential of the latter, in common with
the CENPV-related loci, is also supported by data from
PeptideAtlas28. Of the remaining cases, one represents our
single agreement with the 404 translated lncRNAs proposed by
Wilhelm et al.15 (ENST00000424358), leaving 9 protein-coding
genes that represent novel discoveries.
These annotations have resulted from a combination of the
proteogenomic data presented here and the HAVANA manual
annotation process, which incorporates next-generation tran-
scriptomic data sets such as RNAseq29, CAGE30 and polyAseq31
that were not available during the genome-wide annotation phase
of the GENCODE project. Certain pseudogenes, for example,
were previously wrongly annotated since correct transcript
structures could not be deduced, a problem confounded by 11
of the 16 novel protein-coding genes having single-exon CDS.
Incorrect transcript structures can also prevent the identification
of CDS based on conservation and paralogy. This is illustrated in
Fig. 5a, which shows a protein-coding gene reconstructed on
the site of a shorter pseudogene of TEX13A. RNAseq data is
required to support the transcript structure, where testis-specific
transcription is observed in agreement with the proteomics
results, and the 714 aa CDS shows widespread conservation
across mammalian genomes. In total, 15 of the 16 novel protein-
coding genes either display mammalian conservation beyond
primates or are putative members of known gene families.
The outlier is shown in Fig. 5b, an endogenous retroviral element-
associated CDS with conservation limited to certain primate
genomes.
Despite the conservative and rigorous criteria presented here,
90% of our novel peptide identifications have not led to
annotation, for two main reasons: either annotation did not
make biological ‘sense’ in a transcriptomic context, or there
was an absence of orthogonal supporting evidence for the
translation or transcription of the model. In the latter case, we
note that numerous identifications were made solely within
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Figure 3 | Tissue peptide specificity histograms. Plots showing the numbers of significant peptides identified for each tissue, depicted by tissue
specificity and coding status (CDS/non-CDS). (a) This first plot shows the total number of significant peptides identified in each tissue, the majority of
these being from known proteins expressed in multiple tissues. (b) This plot zooms in on the number of peptides from known proteins that are only
observed in a single tissue. (c) This histogram shows only significant peptides mapped to novel proteins. (d) This final plot zooms down on those novel
peptide identifications that are observed in a single tissue.
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Cufflinks-derived RNAseq models; none of these led to protein-
coding annotation, despite many of these peptides appearing to
have good PSMs. In fact, few of these structures were seen to be
supported by orthogonal transcript evidence, and so could not be
added to GENCODE even as lncRNAs. Since proteogenomic
surveys must be wary about alternate peptide explanations
and the persistence of false positives, these non-annotations are
therefore suggestive in this regard. Due to the difficulty in
confirming peptide-to-protein inference, many of these novel
peptide assignments may be correct but originating from a
protein source not considered in our search space. Although the
peptide data was essential in highlighting the putative CDS in
each of these cases, it was the orthogonal data sets that ultimately
led to annotation, in particular the observation of mammalian
conservation. For illustration, Fig. 6 compares an 11 aa lncRNA-
associated peptide (Fig. 6a) with a 19-aa peptide identified from
an RNAseq model (Fig. 6b). The shorter peptide identifies a novel
63-aa CDS exhibiting strong vertebrate conservation, with
striking eye-specific transcriptomic data matching the identified
peptide. In contrast, the longer peptide is found 4 aa downstream
of a STOP codon within a LINE transposon, in a region that
shows no signature of protein-coding evolution. Indeed, we did
not annotate any lineage-specific CDS in the single-peptide list,
even when they could be linked to canonical initiation codons.
We propose that lineage-specific CDS should only be annotated
based on the presence of multiple, high-quality and manually
validated peptides, unless other sources of experimentally derived
supporting evidence are available.
Pseudogenes provide a particular interpretative challenge; such
loci account for the majority of identified novel peptides. These
loci differ from the pseudogenes converted to protein-coding
genes previously discussed; they contain sequence disablements
such as frameshifts or premature termination codons, whereas
the latter are bona fide protein-coding genes previously mis-
annotated. One could assume that pseudogene peptides are
incorrect, given that these loci are traditionally thought of as
being non-functional. Our initial concern was that peptides
attributed to pseudogenes may actually derive from paralogous
loci outside the search space, or from allelic variant forms of the
parent genes. We found little evidence for these scenarios,
although it is plausible that some pseudogene peptides could be
explained by undocumented parental allelism, the presence of
paralogous loci within reference assembly gaps, the existence
of unappreciated copy number variation or retro-transposition
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Figure 4 | High-stringency peptide filtering regime. This workflow lays out the extensive filtering applied to search results before being passed on for
genome annotation. (a) Results for multiple search engines are merged requiring PSMs to match between the different engines. The worst posterior error
probability (PEP) between the matching search engines is carried forward. PSMs are then filtered by false discovery rate (FDR), PEP and peptide length.
Contaminants are removed prior to protein inference. Peptides with CDS matches are mapped to Ensembl and stored while novel and non-CDS only
peptides are further filtered. (b) Non-CDS peptides are first filtered to increase confidence in identification. (c) These peptides are then examined for
alternative explanations or existing annotation. (d) The remaining non-CDS peptides are assigned a priority annotation score and inferred into novel or
non-CDS genes. (e) The final set of ranked proteins undergoes manual inspection of spectra, validation against RNAseq data sets and is passed to manual
annotators for review.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms11778
6 NATURE COMMUNICATIONS | 7:11778 | DOI: 10.1038/ncomms11778 | www.nature.com/naturecommunications
Table 1 | Novel GENCODE protein-coding annotations.
Vega ID Protein model(s) matched Original biotype Gene description #Unique
peptides
Score CDS
size
Chr
OTTHUMG00000021534 AUGUSTUS Pseudogene Gene similar to CENPV 11 1,616.05 287 x
OTTHUMG00000191517 AUGUSTUS Pseudogene Gene similar to CENPV 9 1,397.35 272 x
OTTHUMG00000024197 RNAseq Pseudogene MOAP/PNMA-like gene 3 597.06 647 x
OTTHUMG00000190648 RNAseq Pseudogene Gene similar to TEX13A 3 518.91 714 x
OTTHUMG00000150367 lncRNA lncRNA HERV-related sequence 3 466.01 109 19
OTTHUMG00000032333 lncRNA lncRNA Unknown 2 373.14 71 20
OTTHUMG00000188075 Pseudogene, RNAseq, AUGUSTUS Pseudogene Cancer/testis (C/T) gene 2 308.09 324 x
OTTHUMG00000021284 Pseudogene, AUGUSTUS Pseudogene MAGEB6P1 1 229.67 407 x
OTTHUMG00000191553 RNAseq, AUGUSTUS Nothing Weak homology to LBH 1 217.25 108 14
OTTHUMG00000067448 RNAseq Pseudogene MOAP/PNMA-like gene 1 215.47 578 x
OTTHUMG00000179794 Pseudogene Pseudogene Myosin XVB 1 209.93 3,064 17
OTTHUMG00000022468 lncRNA lncRNA Weak homology to SMIM10 1 208.01 78 x
OTTHUMG00000007539 lncRNA lncRNA Unknown 1 128.43 63 1
OTTHUMG00000167731 lncRNA lncRNA Unknown 1 109.10 59 11
OTTHUMG00000158324 AUGUSTUS lncRNA Zinc-finger like gene 1 96.87 203 7
OTTHUMG00000191600 AUGUSTUS Nothing Unknown 1 89.64 177 1
OTTHUMG00000019158 50 UTR Protein-coding INPP5F 2 194.26 593 10
CDS, coding sequences; UTR, untranslated region.
Based on the peptide evidence discovered in this study combined with additional orthogonal evidence, 17 annotations have been added or updated in the GENCODE gene set. The single addition within a
previously existing protein-coding gene is highlighted in bold at the bottom of the table. The ‘Vega ID’ identifies the updated annotation in the latest release, while the ‘Protein Models Matched’ lists the
search database sequence types matched by the peptides. The ‘Original Biotype’ represents previous annotation at each locus and the ‘Gene Description’ column shows known gene name or gene
homology. Genes are described as ‘unknown’ where no homology to known protein families or functional domains could be detected. The final columns show the number of unique peptides matching
each protein model, the summed priority annotation score of these peptides, the length of the new CDS, and the chromosome on which this gene is located. A more complete version of this table can be
found in Supplementary Dataset 1.
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Figure 5 | Novel protein-coding loci supported by multiple PSMs. (a) Protein-coding gene OTTHUMG00000190648 replaces processed pseudogene
TEX13P on chromosome X. The latter had been based on an observed region of homology to TEX13A. The novel CDS is supported by four high-quality
peptides unique to the locus (RNASEQ00000005460); one peptide aligns three times within a tandem repeat region. Transcription is apparently
testis-specific in both the Illumina BodyMap and Human Protein Atlas RNAseq libraries; the BodyMap read coverage graph produced by Ensembl is
shown below the model. The transcription start and end points of the novel structure are supported by CAGE data from the FANTOM5 project55
and polyAseq data from Derti et al.31 (not shown). PhastCons 100-way data are shown in blue (genome.ucsc.edu); while the CDS is conserved in mammals,
there is length variation within the repetitive region. An orthologous gene model has been added to the mouse GENCODE annotation set as
OTTMUSG00000054810. (b) lncRNA OTTHUMG00000150367 (ERVK1) has been reannotated as a protein-coding gene with a 109-aa CDS. This CDS is
entirely found within repeat-masker sequence corresponding to the HERVK3, although the first exon is found within non-repeat sequence. RNAseq libraries
indicate that the transcription of this locus is widespread, for example, found in all 27 Human Protein Atlas tissue RNAseq libraries generated by Fagerberg
et al.56 as processed by Hezroni et al.57 (heart, kidney and liver coverage graphs are shown below the model), while the three high-quality PSMs generated
here have been identified in 9 tissues. The most distant orthologue that can be confidently annotated is found in the rhesus macaque genome.
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events that are not fixed in the human lineage. These cases would
be difficult to confirm without proteomic and transcriptomic
experiments being conducted on paired samples.
It is interesting that many of the processed pseudogenes in our
lists belong to families with dozens of copies, for example, the
GAPDH family. All except one of these parental genes are
described by Protein Atlas32 as producing a protein found at ‘high
levels’ in multiple tissues. It could be that highly transcribed genes
produce more pseudogenes due to the increased chance of
retro-transposition, raising the likelihood that one or more will
gain the potential to be translated. Alternatively, it may simply be
that higher levels of protein expression inevitably lead to an
increase in the capture of dissonant spectra, or perhaps increase
the likelihood of cryptic in situ modifications that are
subsequently misinterpreted. Ultimately, it is clearly logical to
be conservative in the interpretation of pseudogene peptide
evidence. As for lineage-specific lncRNA CDS, pseudogene
translation should only be considered for annotation where
more than one high-quality unique peptide can be linked to an
in-frame initiation codon. For such cases, a novel biotype
‘translated pseudogene’ has been created in GENCODE;
conversion to full-protein-coding gene status will only occur
when the functional basis of the locus is experimentally
established.
Proteomics has potential as a powerful tool for genome
annotation, allowing validation of existing protein-coding
annotations and discovery of novel coding regions. It offers
substantial benefits for less refined genomes, although our
identification of 17 novel coding regions demonstrates that mass
spectrometry has an important role to play in human annotation.
It is notable that despite the high levels of stringency and filtering
used, the majority of peptides identified outside the known
protein-CDS have not led to novel annotations, emphasizing a
need for vigilance in interpreting such data sets and the need to
handle pseudogenes identified by proteomics with care. Recent
years have seen a rapid increase in the number of proteogenomics
experiments published, many of which strive to obtain the largest
coverage of peptides and novel identifications possible. The size of
these data sets places a burden on annotators, as they strive to
separate those genuine identifications from the inevitable set of
spurious peptides. We believe that proteogenomics should take a
‘quality-over-quantity’ approach, as exemplified by the integrated
mass spectrometry and annotation workflow presented here. In
addition, we propose a priority annotation score for ranking
novel proteomics evidence. Although of limited benefit in this
study, the higher scoring peptides did lead more frequently to
new annotation, and we believe this would be of great value in
non-reference genomes. Above all, proteomics data sets should
not be interpreted in isolation, rather they should be considered
as a single component of an annotation strategy that also includes
high-throughput transcriptomic data coupled with comparative
analyses.
VJQMQVAGEJK
Human --MRFRRLTPGYFRVLQMQVAGELKAEPRSLLAGVVATVLAVLGLGGSCYAVWKMVGQRRVPRAP*
Mouse --MRFRRLTPGYFRVLQMQVAGELKAEPRSPLVGIVATLLAVLGLGGSCYAVWKMVKQRQPSQAP*
Dog --MRFRRLTPGYFRVLQMQIAGELKAEPRSPLAGIVATLLAVLGLGGSCYAVWKMVGQRRPPQA*
Opossum --MRFGRLTPGYFRRLEMQVAGELEAEPRNQLMGALATLLAVCGLGLSFYSVRQLMDQGKSPKTP*
Tetraodon MIIRLGRLTPGYFRLLQRQVAGEVQMQPQDRAVNQIAMMLAILGLGLSYYSAKQMTEKVQVQPAP*
p1@ENST00000448923
5’
PhyloCSF
OTTHUMG00000007539 
ZNF593
CUFF.34264.1
**LFNKLQHSLIQFFSNMLLETESKSKFTAQKLRLT*Q*
JQHSJJQFFSNMJJETESK
Repeat masker
EXON 3
a
b
Figure 6 | Identifying novel protein-coding regions based on single peptides. (a) A novel 63-aa CDS has been identified within
OTTHUMG00000007539, previously lncRNA ENST00000407889. Alternatively spliced transcripts have been omitted for clarity. PhyloCSF plots are
shown for the relevant reading frames3: the CDS is conserved in mammals, while a putative orthologue in the tetraodon genome is identified within an
unplaced contig. The peptide (which spans the splice junction) was found only in retina. Strikingly, all transcriptomic data identified in each highlighted
species is limited to eye tissues: human CAGE data from FANTOM5 (ref. 55; green triangle) identifies TSS within corneal and lens epithelial cells, vitreous
humour and retina tissues; mouse CAGE data identifies TSS within eyeball tissue; the 6 splicing human ESTs identified are all derived from eye tissues,
as are each of the 20 tetraodon mRNAs, 10 dog ESTs and 3 mouse mRNAs identified (not shown). (b) A 19-aa peptide is found within Cufflinks gene
CUFF.34264.1, containing 3 exons spanning B175 kb of genomic sequence on chromosome 12. However, we do not observe support for these introns,
the TSS or the transcript endpoint. The peptide falls within the final exon, which does not show evidence of conservation in PhastCons 100-way plots,
and entirely within repeat-masker sequence (specifically an L1M6 element; www.repeatmasker.org). The ORF to which the peptide aligns does not contain a
canonical initiation codon, and the distance between the flanking STOP codons is just 34 aa.
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Methods
Raw data sources. Three large, publicly available human tissue proteomics data
sets were downloaded from the Internet. The first, containing 2,212 raw files, was
generated by the Pandey lab at Johns Hopkins University14, and was downloaded
from ProteomeXchange via the PRIDE33 repository (www.ebi.ac.uk/pride/archive/
accession PXD000561). These were higher-energy collisional dissociation (HCD)
raw files, from Thermo Scientific Orbitrap instruments, comprising 85 fractionated
experimental samples covering 30 different human adult and foetal tissues. The
second data set was the Human BodyMap data generated by the Kuster lab
at the Technische Universita¨t Mu¨nchen as part of their draft human proteome
publication15, which was downloaded from ProteomicsDB (www.proteomicsdb.org
accession PRDB000042). This data set consists of 1,087 HCD and collision-induced
dissociation (CID) Thermo Scientific raw files from 48 experiments covering 36
different tissues. The final data set which was also used in the draft human
proteome was generated by Paul Cutler at Roche Pharmaceuticals and originally
deposited in PeptideAtlas34 in 2011. This data was also downloaded from
ProteomicsDB (accession PRDB000012) and contains 1,618 CID Thermo Scientific
raw files covering 10 different human tissues.
Spectral processing. Each raw file was converted to the standard mzML format
using the ProteoWizard (v3.0.6485) msconvert tool35. Following conversion, the
data was processed with TOPP tools from OpenMS (pre-v2.0 development build)
(Fig. 1)36. All spectra were centroided using the PeakPickerHiRes tool, and files
from fractionated experiments were merged using the FileMerger tool (up to a
maximum file size of 2GB). A small number of the raw files appeared to contain no
spectra and were not included in the conversion. The final set of 195 mzML files
comprised 52,236,496 spectra.
Sequence database creation and preparation for searching. A comprehensive
human sequence database in FASTA format was created by combining six parts.
These included, the complete human GRCh38 GENCODE v20 (ref. 37) CDS
translated sequences; the UniProt38 human reference proteome from May 2014;
common contaminant protein sequences downloaded from Max Planck Institute of
Biochemistry (http://maxquant.org/contaminants.zip) and HLA sequences from
(http://www.ebi.ac.uk/ipd/imgt/hla/download.html); a selection of non-coding
gene sequences from GENCODE v20 including pseudogenes, lncRNA sequences
and 50 untranslated region sequences; novel sequences generated using the
AUGUSTUS gene predictor39; an additional set of two-way consensus pseudogene
predictions from Pseudogene.org (December 2013); and three-frame translated
RNAseq transcript sequences. RNAseq transcript models were imported from three
sources: Ensembl RNAseq models assembled using data from the Illumina Human
BodyMap 2.0 project, which captures transcription in 16 human tissues (http://
www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-513); models generated by the
Kellis lab at MIT using also Human BodyMap data and the Scripture software40;
and models produced by Caltech and CSHL using RNAseq data from different
ENCODE cell lines and the Cufflinks software41. GENCODE non-coding gene
sequences, AUGUSTUS predictions, pseudogenes and RNAseq models overlapping
GENCODE coding regions were filtered out from the final sequence database. For
some of the databases the sequences needed to be translated into amino acids from
nucleotide sequences; this was done using the EMBOSS (v6.6) six-pack tool42
to generate three-frame translations of the sequences, splitting stop codons into
separate ORFs with a minimum length of 10 amino acids. Finally, a set of
randomized decoy sequences of equal size to the target database was generated
using the Mimic tool (https://github.com/percolator/mimic) and appended to the
database. To account for isobaric peptides all isoleucine (I) residues within the
database were replaced with leucine (L); after searching, leucine residues were
always converted to the ambiguous code J. All protein accessions were formatted to
include the source database, a unique identifier and if available a genomic locus.
Supplementary Table 1 contains a summary of the sequence database components
including the number of proteins, peptides and amino acids. In terms of distinct
tryptic peptide sequences, the known coding portion of the database contained
787,587 peptides and the novel sequences provided an additional 4,211,835
peptides.
Spectral identification and database search pipeline. Figure 1 describes the
overall identification and analysis pipeline, including the OpenMS/TOPP-based
workflow that was used to run the database searches for the three data sets.
The TOPP tool MascotAdapterOnline was used to submit mzML files to a
Mascot Server v2.4 (Matrix Science) cluster; the in-house developed TOPP tool
MSGFPlusAdapter was used to run MS-GFþ v10089 (ref. 43) on the same
files across a large computer cluster. Two wrappers were implemented to run
MascotPercolator v2.08 (refs 44,45) and the msgf2pin/Percolator v2.08-1 (ref. 46)
tool combination to optimize and rescore the Mascot and MS-GFþ results,
respectively. In addition, SEQUEST combined with Percolator47 was used to search
the data in a Proteome Discoverer v1.4 (Thermo Scientific) workflow. All database
searches were performed with a precursor tolerance of 10 p.p.m. and a fragment
tolerance of 0.02Da for HCD spectra and 0.5Da for CID spectra. Up to three
missed cleavages were allowed. The fixed modification carbamidomethyl
(þ 57.0214) was specified for all cysteine residues. In addition, the following
variable modifications were used in the searches: N-terminal acetylation
(þ 42.01056), N-terminal carbamidomethyl (þ 57.0214), deamidation of
asparagine and glutamine residues (þ 0.984), oxidation of methionine
(þ 15.9949), and N-terminal conversion of glutamine and glutamic acid to
pyro-glutamine ( 17.0265,  18.0106). The multiple search results of this
workflow were converted into mzTab formatted files and uploaded along
with the mzML spectra and FASTA search database to the PRIDE repository
(http://www.ebi.ac.uk/pride/archive/)33 under accession PXD002967.
Initial results processing and filtering. Custom Perl scripts were used to parse,
merge and filter the results of each search engine (Fig. 3). The results from the
multiple search engines were first merged and filtered so that every PSM had the
same identification in at least two of the three search engines. The highest (least
confident) PEP value was retained in each case. The PSMs were then filtered
keeping only matches with a q-value of r0.01 (1% FDR), a PEP of r0.05 and a
peptide length of at least seven amino acids. PSMs matching contaminant or decoy
sequences were also removed. Proteins were then inferred from the final list of
peptides, taking a simple approach to cluster proteins that matched the same set of
peptides, so that each protein cluster had at least one unique peptide. To calculate
the number of genes identified by these proteins, we mapped GENCODE CDS and
UniProt accessions back to Ensembl gene identifiers. Several protein clusters did
not contain a GENCODE CDS nor a UniProt accession; these non-CDS protein
identifications were separated and further filtered for genome annotation.
Supplementary Fig. 4 displays the  10log(PEP) score distribution of CDS
and novel PSMs.
Non-CDS peptide analysis. Non-CDS identifications, which we define as peptides
uniquely matching a single sequence not found in the GENCODE CDS, UniProt
database nor the contaminant sequence databases were further filtered to an
increased stringency. The filtering criteria included, a 0.01 PEP threshold, a
maximum peptide length of 29 amino acids, only fully tryptic peptides, and a
maximum of two missed cleavages. In addition after identifying an enrichment of
deamidated and N-terminally carbamidomethylated PSMs in the non-CDS data
set, PSMs so modified were also removed. Peptides were also checked to make sure
that modifications were identified on the correct N-terminal residues in the case of
pyroglutamate conversions. BLASTp48 with parameters optimized for short
sequences was used to search an up-to-date combined GENCODE V22 (ref. 37),
RefSeq V70 (ref. 49), NeXtProt (release 28 April 2015)50 and UniProt (release
May 2015)38 sequence database. Any matches were removed from the data set.
A Perl script was then used to search the GENCODE CDS removing peptides with
less than two mismatches to known proteins.
Priority annotation score. A score for each peptide was computed using a set of
peptide features. The following equation describes the scoring for each protein
based on the summed priority annotation scores of its distinct unambiguous
peptides:
a ¼
X
 10 log 10 Pið ÞþUi þ MiWm
 
þ Li þ Eiþ DiWd
 
þ Ri
Wr
  
Where
Pi represents the best PEP obtained for each peptide, representing the
confidence in this peptide.
Ui is the number of significant unmodified PSMs identifying each peptide, this
increases the score of more abundant, repeatedly sampled peptides.
Mi is the number of modified PSMs significantly identifying each peptide, this is
adjusted by Wm (initially set to 5), again this increases the score of more abundant
peptides; however, the adjustment makes modified forms of the peptide less
influential than unmodified PSMs.
Li represents the peptide amino-acid length.
Di is the delta score difference between 1st and 2nd ranked peptide spectrum
assignments, adjusted by Wd (initially set to 10). This feature boosts the score
where there is less ambiguity in sequence assignment, as this value can be large so it
is divided by 10 to avoid it dominating the score.
Ri is the number of samples or replicates significantly finding each peptide this
is adjusted by Wr (initially set to 5). This feature increases confidence in a novel
peptide and reduces the chance of it originating from a variant sequence. In this
study, there are over 100 samples included, hence we applied a weighting to
prevent this feature overly influencing the final score.
Ei is the entropy for the peptide sequence calculated using information theory
using this formula:
e¼ 10
P  niN log niN 
log2
Where
ni is the number of occurrences of each amino-acid type in the peptide and N is
the length of the peptide. This feature increases the scores of more complex
peptides.
The Wm, Wd and Wr weightings were initially set to values that scale the
peptide features to the same magnitude and avoid any feature overly biasing the
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score. For use beyond this study these values can be optimized, as well as additional
features added to suit the type of experimental data and annotation evidence
required. Supplementary Fig. 5 shows a histogram of the resulting scores for
peptides that led to novel annotations and those that were rejected on manual
inspection of the genomic loci.
RNAseq analysis and validation of novel genes. After retrieval of the publicly
available raw data of the ArrayExpress data set with the accession number
E-MTAB-2816 (ref. 27), the RNAseq libraries were analysed with iRAP using
TopHat2 (ref. 51) to map reads to the reference genome (GRCh38.p3) and
HTSeq-count52 to assign reads to the Ensembl release 76 gene annotation53
using default parameters. Reads Per Kilobase of transcript per Million (RPKM)
values were then calculated with the internal function provided by iRAP. For each
tissue, gene expression levels were calculated by first taking the mean of the
technical replicates before calculating the mean of the biological ones. When the
VEGA IDs of the genes had corresponding ENSEMBL 76 gene IDs, those IDs were
directly used to assess the gene expression. When this was not the case, the
coordinates of the genes were retrieved from the latest VEGA release and then the
windows of interest were plotted on merged bam files (one bam per tissue)
obtained from TopHat2. The Supplementary Dataset 1 includes the number of
paired reads that have been counted for each novel gene on the merged bam files
normalized by the number of initial samples for each tissue.
Manual genome annotation. Manual annotation was performed according to the
HAVANA criteria as defined for the GENCODE project37. A novel ‘logic tree’ was
used to allow annotation decisions to be made consistently; see Supplementary
Fig. 3. Furthermore, a tblastn query was performed for each peptide on the primary
list (see main text) to check whether related sequences found outside the search
space could provide alternative explanations for the match; this was also done for
those peptides on the secondary list seen to highlight putative coding regions. For
pseudogene-associated matches on the primary list, dbSNP54 was queried to
investigate whether the PSM could also belong to a variant form of the parent
locus.
Data availability. All search results along with the spectra and sequence database
are available in the PRIDE repository (http://www.ebi.ac.uk/pride/archive/) under
accession PXD002967. The authors declare that all other data supporting the
findings of this study are available within the article and its Supplementary
Information files.
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